Medical Equipment ETF (159873) received a net subscription of 30 million shares yesterday, with nearly 20% of the target index comprising brain-machine interface components. Institutions: Brain-machine interfaces are transitioning from laboratory experiments to the brink of industrialization.

What opportunities do AI and institutions see for the commercialization of brain-computer interfaces?

Yesterday (March 23), the Shanghai Composite Index fell 3.63%, narrowly holding above 3,800 points. The CSI All Share Index for Medical Care Equipment and Services declined 4.69% by the close. Among its constituent stocks, Heshun New Materials rose over 1%.

Regarding related ETFs, the Medical Equipment ETF (159873) had a trading volume exceeding 30 million yuan, with a turnover rate over 11%, ranking first among similar funds; Wind financial terminal data shows that this ETF received 30 million net subscriptions on that day.

In terms of capital flow, Wind data indicates that as of March 20, the Medical Equipment ETF (159873) had a net inflow of 185 million yuan over the past 60 trading days.

The ETF tracks the CSI All Share Index for Medical Care Equipment and Services, which has a high allocation to brain-computer interface concepts, accounting for nearly 20%. Its constituent stocks include nearly 80% from the STAR Market and ChiNext, covering brain-computer interface concept stocks such as Sanbo Brain, Xiangyu Medical, and Weis Medical.

According to Securities Times, on March 13, the world’s first invasive brain-computer interface medical device was officially approved for listing. On March 15, the National Healthcare Security Administration proactively coordinated and provided services to assign a medical insurance code to this product, successfully bridging the critical link from approval to clinical application. This marks the transition of the brain-computer interface industry from a “blueprint” to a “fast lane” for implementation.

Xiangcai Securities stated that currently, brain-computer interfaces are the most prominent focus in the medical technology field. Driven by top-level policies, breakthroughs in core technology, and payment guarantees, the industry is moving from laboratory research toward industrialization. Especially for needs related to paralysis, stroke, and ALS, the application directions are clear, and the demand outlook for related implantable system consumables is expanding.